$76.51▾ 2.01%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$2.29cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
52th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+55.4%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares turns 229¢ of every reported profit-dollar into real cash. Revenue is growing strongly year over year. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$0.98
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin9.6%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$840.85M
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.